A PYMNTS Company

US: Biopharmaceutical merger announced

By  |  March 8, 2015

Winston-Salem-based Targacept plans to merge with Catalyst Biosciences Inc., a privately held biopharmaceutical company based in San Francisco.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    If approved by regulators and shareholders, operations will be absorbed by Catalyst Bioscience in San Francisco, ending Targacept’s 15 year run in Winston-Salem.

    The focus of the merger will be to use engineered human proteases to develop next-generation biopharmaceuticals with an improved efficacy and therapeutic index to treat major diseases.

     

    Full Content: GEN

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.